research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
Search
for
Sort by
Research
750-780 / 1000+ results research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
research Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up
Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
research Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
Biologics for severe asthma have known side effects, but some new risks need more study.
research T helper type 2 immune response in alopecia areata
Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.
research Correlation of Immunological Variables of Interleukin-17 and Heat Shock Protein-70 In Ethnic Women with Polycystic Ovary Syndrome
Treatment improved PCOS symptoms and reduced BMI and certain immune factors.
research Microneedle‐mediated Delivery of Immunomodulators Restores Immune Privilege in Hair Follicles and Reverses Immune‐Mediated Alopecia
A microneedle patch can help regrow hair by restoring immune balance in hair follicles.
research Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
research Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata
Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.
research Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab
Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
research Alopecia secondary to severe discoid lupus responding to anifrolumab
Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
research 42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)
Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
research EVALUATION OF QUALITY OF LIFE AMONG TURKISH WOMEN WITH HIRSUTISM: A CROSS SECTIONAL STUDY
Hirsutism significantly lowers the quality of life for Turkish women.
research JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
research Hair Regrowth in a Child with Seasonal Alopecia Areata While Receiving Subcutaneous Aeroallergen Immunotherapy: A Case Report
Immunotherapy helped a 5-year-old boy regrow hair and prevent seasonal alopecia areata.
research Azathioprine
A woman experienced hair loss, nail changes, bone marrow suppression, and low blood protein after taking azathioprine.
research Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
research Mogamulizumab‐induced alopecia. Multicentric case series: Clinical, trichoscopic and histological characterization
Mogamulizumab can cause hair loss, often linked to a better treatment response.
research Hirsutism
Medication can effectively reduce hair growth and improve life quality for women with hirsutism.
research Editorial: Targeted immunological therapies in dermatology
Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.
research Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis
Methotrexate for rheumatoid arthritis often causes side effects like diarrhea, fatigue, and hair loss, especially at higher doses.
research 0877 Activated wound phenotype and microbial dysbiosis are driven by AhR suppression in hidradenitis suppurativa tunnels
Reduced AhR signaling in HS tunnels leads to persistent inflammation and microbial imbalance.
research The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target
Targeting CD200 could be a new treatment for rheumatoid arthritis.
research HORMONAL THERAPY IN DERMATOLOGY
Hormonal therapy is a treatment option for acne, the only medical treatment for hirsutism, and the most promising for androgenetic alopecia.
research Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
research Concomitant Vitiligo and Psoriasis in a Patient Treated with Interferon Alfa‐2a for Chronic Hepatitis B Infection
A girl developed vitiligo and psoriasis after hepatitis B treatment, and stopping the treatment didn't help.
research Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
Blocking IL-8 can reduce skin rashes from cancer treatment.
research Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis
A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.